Skip to Main Content

Author Details

Hendrik Van Poppel
University Hospitals Leuven
1981
571
86
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37537111Impact of the Standardization of Penile Cancer Care on the Quality of Care, Outcomes, and Academic-driven Centralization in a Single eUROGEN Referral Center.Eur Urol Focus2024
36167599ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.Eur Urol2023
37704541Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.Eur Urol2023
37573666Morbidity of elective surgery for localized renal masses among elderly patients: A contemporary multicenter study.Eur J Surg Oncol2023
37058168Radioligand therapies in cancer: mapping the educational landscape in Europe.Eur J Nucl Med Mol Imaging2023
37284048New-onset Chronic Kidney Disease After Surgery for Localised Renal Masses in Patients with Two Kidneys and Preserved Renal Function: A Contemporary Multicentre Study.Eur Urol Open Sci2023
37441346How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration.Eur Urol Open Sci2023
37473914Men and cancer: Tackling the excess burden.J Cancer Policy2023
36609009The Future of Medical Devices in Europe Is at Stake: Concerns over the Implementation of the Medical Devices Regulation 2017/745.Eur Urol2023
36462750Cancer literacy - Informing patients and implementing shared decision making.J Cancer Policy2023
36631353Estimating Postoperative Renal Function After Surgery for Nonmetastatic Renal Masses: A Systematic Review of Available Prediction Models.Eur Urol Oncol2023
36372636Predicting short- and long-term renal function following partial and radical nephrectomy.Urol Oncol2023
34176768Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.Eur Urol Oncol2022
35697600EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy.Eur Urol Oncol2022
35820680Diagnosing prostate cancer at a curable stage means providing PSA tests to asymptomatic patients.BMJ2022
35596017Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.World J Urol2022
36569505Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer.BJUI Compass2022
36100483Epidemiology of Renal Cell Carcinoma: 2022 Update.Eur Urol2022
36353657Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study.Eur Urol Open Sci2022
36163308Shaping the Undergraduate Curriculum in Europe: Consensus Statement from the European School of Urology.Eur Urol2022
36252165European Cancer Organisation's Inequalities Network: Putting Cancer Inequalities on the European Policy Map.JCO Glob Oncol2022
35974245Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.Nat Rev Urol2022
35082164Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer.Mol Cancer Res2022
34922897Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer.Eur Urol Focus2022
34099385Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study.Urol Oncol2022
32417995Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by <sup>68</sup>Ga-PSMA-11 PET/CT or <sup>11</sup>C-Choline PET/CT: impact of postoperative treatments.World J Urol2021
33485762C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.Urol Oncol2021
33540773Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.Cancers (Basel)2021
33580296Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review.World J Urol2021
34738091Essentials for Standardising the Undergraduate Urology Curriculum in Europe: Outcomes of a Delphi Consensus from the European School of Urology.Eur Urol Open Sci2021
34735807Nuclear medicine theranostics comes of age.Lancet Oncol2021
34526701Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.Nat Rev Urol2021
34407909Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.Eur Urol2021
34716119Epidemiology and Prevention of Prostate Cancer.Eur Urol Oncol2021
34448678Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications.Acta Oncol2021
34364829A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.Eur Urol Oncol2021
34362692Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.Clin Genitourin Cancer2021
31810893Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy.Eur Urol Oncol2021
33225759Current and emerging therapies for localized high-risk prostate cancer.Expert Rev Anticancer Ther2021
33281109Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients.Eur Urol Focus2021
33129581IMAGINE-IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines.Eur Urol2021
33419680Standardization in Surgical Education (SISE): Development and Implementation of an Innovative Training Program for Urologic Surgery Residents and Trainers by the European School of Urology in Collaboration with the ESUT and EULIS Sections of the EAU.Eur Urol2021
33384200Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission.Eur Urol2021
32571744Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors.Eur Urol Focus2021
31411993Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer.Eur Urol Oncol2020
33564664Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology.Biomed Hub2020
31753752EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>â¿ </sup>: Under the Auspices of the EAU-ESMO Guidelines Committees.Eur Urol2020
31992464European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management.Eur Urol2020
32068488Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup>Ga-PSMA and <sup>11</sup>C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections.J Urol2020
31975650Prognostic score predicts overall survival following complete urinary tract extirpation.Scand J Urol2020
  • 1 - 50 of 571

Recommended Authors

Giovanni Motterle
Mayo Clinic
Career Start Year 2017
Number of shared co-authors 8
Izak Faiena
Columbia University Medical Center
Career Start Year 2010
Number of shared co-authors 1
Amirali Salmasi
University of California San Diego
Career Start Year 2005
Number of shared co-authors 2
Jonathan L Wright
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 14
Edward Rowe
Bristol Urological Institute, Southmead Hospital
Career Start Year 2004
Number of shared co-authors 6
Jun Hyuk Hong
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 2002
Number of shared co-authors 4
Nimish Shah
Cambridge University Hospitals NHS Foundation Trust
Career Start Year 2002
Number of shared co-authors 5
Tim Dudderidge
University Hospital Southampton NHS Foundation Trust
Career Start Year 2002
Number of shared co-authors 4
Byong Chang Jeong
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2001
Number of shared co-authors 4
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 16
Omer Acar
University of Illinois at Chicago
Career Start Year 1996
Number of shared co-authors 2
Alan Thompson
The Royal Marsden NHS Foundation Trust
Career Start Year 1996
Number of shared co-authors 4
J??rn Kamradt
Clinic of Urology and Pediatric Urology, University of Saarland
Career Start Year 1996
Number of shared co-authors 1
Feliksas Jankevicius
Clinic of Gastroenterology, Vilnius University
Career Start Year 1995
Number of shared co-authors 1
Louis Lacombe
CHU de Quebec-Universite Laval
Career Start Year 1994
Number of shared co-authors 10
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 19
Douglas S Scherr
New York-Presbyterian Hospital
Career Start Year 1994
Number of shared co-authors 20
David Nicol
The Royal Marsden Hospital
Career Start Year 1993
Number of shared co-authors 5
Choung-Soo Kim
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1993
Number of shared co-authors 11
Alexandre R Zlotta
University Health Network, Princess Margaret Cancer Center, University of Toronto
Career Start Year 1993
Number of shared co-authors 17
Antonio Finelli
Princess Margaret Cancer Centre, University Health Network and University of Toronto
Career Start Year 1993
Number of shared co-authors 29
Raymond S Lance
Washington State University Elson S. Floyd College of Medicine
Career Start Year 1992
Number of shared co-authors 10
Bernd Wullich
University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)
Career Start Year 1989
Number of shared co-authors 5
Damien Bolton
University of Melbourne
Career Start Year 1988
Number of shared co-authors 8
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 33
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 17
Franz Recker
PolyClinic St. Moritz/Scuol
Career Start Year 1986
Number of shared co-authors 5
David E Neal
University of Oxford, John Radcliffe Hospital
Career Start Year 1981
Number of shared co-authors 25
Cathy Corbishley
The Institute of Cancer Research
Career Start Year 1977
Number of shared co-authors 4
Keong Tatt Foo
Rutgers Cancer Institute of New Jersey
Career Start Year 1975
Number of shared co-authors 1

Collaborators

Alberto Briganti
IRCCS San Raffaele Scientific Institute
Co-authored papers 55
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 34
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Co-authored papers 24
Gert De Meerleer
University Hospitals Leuven
Co-authored papers 22
Michel Bolla
universite Grenoble-Alpes (UGA)
Co-authored papers 20
Giorgio Gandaglia
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Co-authored papers 19
James N'Dow
University of Aberdeen
Co-authored papers 15
Arnulf Stenzl
Eberhard Karls University of Tubingen
Co-authored papers 12
Laurence Collette
Belgium International Drug Development Institute
Co-authored papers 11
Monique J Roobol
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 10
Nicolas Mottet
Hospitalier Universitaire de Saint-Etienne
Co-authored papers 8
Theo M de Reijke
Amsterdam University Medical Centers, University of Amsterdam
Co-authored papers 8
Piet Ost
Ghent University, GZA Ziekenhuizen
Co-authored papers 8
Fred Saad
University of Montreal Health Center
Co-authored papers 6
Anders Bjartell
Skane University Hospital, Lund University
Co-authored papers 6
Philip Cornford
Liverpool University Hospitals
Co-authored papers 6
Roderick C N van den Bergh
St. Antonius Hospital
Co-authored papers 5
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 5
Cora N Sternberg
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 5
Hartwig Huland
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Co-authored papers 5
Mark Frydenberg
Monash University
Co-authored papers 4
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Dana E Rathkopf
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 4
Diether Lambrechts
Co-authored papers 4
Stefaan W Van Gool
Co-authored papers 4
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 4
Riccardo Campi
Careggi University Hospital
Co-authored papers 4
Baris Turkbey
National Cancer Institute, National Institutes of Health
Co-authored papers 4
Yves Fradet
CHU de Quebec-Universite Laval
Co-authored papers 4
Release 1.2